Integration of imaging data with immunohistology is a new art. Increased PET and MRI image intensities on rat breast tumor MRI-PET images were reviewed for possible correlation with tumor histology and MALDI imaging tumor characteristics in the light of recent inventions and patents. Increased signal intensities of intracellular (IC) sodium MRI and flouro-2-deoxy-glucose utilization by PET from apoptosis protein rich MALDI visible regions of tumors were positively correlated to chemosensitivity of Taxotere. MCF-7 cancer cell line induced rat tumor MRI-PET images and histology digital images were compared for correlation in pre-and post taxotere treated tumors. For MALDI imaging, iterated protein ion mass spectrometry peak analysis was done using data from laser raster over tumor slices in sequence and 3D tumor volume was simulated for specific peak(s) distribution. A criterion was developed to evaluate malignancy by histology and MRI-PET imaging. For correlation, regression analysis was done using MRI-PET imaging, histology and MALDI imaging data from MCF-7 tumor after 24 hours post-taxotere treatment. Apoptosis indices were calculated by histostaining using pentachrome, feulgen and ss-DNA antibody assay. Review showed sodium MRI and PET signal intensity distribution comparable and measurable in tumor tissue regions. In tumors, taxotere induced an increase in IC-Na MRI signal with decreased tumor size and micro-PET showed FDG uptake increase with decreased tumor size than that of control tumors after 24 hours. Histology features indicated tumor risk (high 'IC/EC ratio', high mitotic index and apoptotic index), decreased tumor viability (reduced mitotic figures, reduced diploidy or aneuploidy and proliferation index) after Taxotere treatment. These features in co-registered IC-Na, PET hypermetabolic and monoclonal antibody (ss-DNA) sensitive regions showed 6% difference. MALDI imaging showed tumor specific protein ion species and their distribution showed empirical correlation (limited visual match) with MRI-PET signal intensities but comparable match with histology features. Recent patents strongly suggest the possibility of sodium MRI and PET multimodal imaging integrated with MALDI-imaging as an non-invasive chemosensitivity assay to monitor the anticancer effect.
INTRODUCTION
Magnetic resonance imaging (MRI) combined with positron emission tomography (PET) microimaging multimodal technique was invented and recently emerged as multimodal molecular imaging tool in experimental tumor pharmaco-dynamic characterization. Matrix Assisted Laser Desorption/Ionization (MALDI) based imaging was invented and proposed as diagnostic technique and it is emerging now as imaging technique to visualize the cancer specific protein(s) for time-dependent monitoring of anticancer chemosensitivity by sodium MRI as research tool in cancer therapy [1] . However, MRI/PET visible tumor image characteristics and association with MALDI-imaging of tumor specific protein still remain a puzzle to correlate them with tumor physiology and histology characteristics due to difficulty of interpretating physical complexity of MRI-PET, *Address correspondence to this author at the Center of Biotechnology, Innovations And Solutions Inc., 3945 west Pensacola Street, #98, Tallahassee, Florida 32304, USA; Tel: 18507027661; Fax: 18503395361; Email: rs2010@columbia.edu, jk32@columbia.edu signal physico-chemical complexity of MALDI signal and cytomorphic complexity of histopathology structural details of tumor [2] . In last 5 years, extensive efforts are made to develop time-of-flight MALDI (TOF-MALDI) as real-time fast imaging technique of accurate analysis of proteins and peptides with detail information of minute protein species by mass spectroscopy (up to nanomoles based on m/z ratio) by combining it with other variant mass spectroscopy SELDI, MALDI-LC, MALDI-TLC methods and modifying sample positioning, matrix composition and laser desorption/ absorption as represented in recent patents [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . These techniques were of limited use to analyze protein composition as m/z peak intensities with or no information of protein distribution. In attempt to develop tissue MALDI imaging as ion distribution maps of selected m/z peaks of high intensities, we report Monte Carlos simulation technique to convert the MALDI peaks as points and display them as digitized simulated 'm/z' protein 'ion peak maps' at matched tissue locations on histology tissue sections coregistered with MRI-PET signal intensity distribution maps of tissue sodium-glucose uptake or oxygen contents. Currently, efforts are focused on integration or fusion of MRI-PET data from in vivo images and MALDI-histology-immunostaining data from ex vivo tissue slides to reconstruct the three-dimensional tissue volume with details of biophysicochemical, structural and molecular makeup of tissue. The present review focuses on physical principles and quantitative approach to explore the possibility of integration and fusion of in vivo and ex vivo tissue data.
Intracellular sodium MRI signal intensity increase in glioma, necrosis, and apoptosis was considered due to leaching out intracellular sodium after the membrane damage [1, 14] . Measurement of intracellular sodium by triple quantum, inversion recovery MRI imaging methods emerged as technique risk-free frominvasive infusion of Schiff reagents [15] . The 18 F-Fluoro-deoxy glucose positron emission tomography ( 18 FDG-PET) dynamic scanning indicated hyper-glycolytic regions in tumor while MRI generated static images [16] .
In following sections, we review our study of MCF-7 injected rat breast tumor illustrating the static deformed PET registration with slice-by-slice MRI sections to demonstrate the point-wise match between MRI-PET signal intensities and protein MALDI peaks or images. A 'quantitative MRI-PET-MALDI criterion' was developed to validate and correlate the MRI/PET microimaging for tumor intracellular sodium signal intensities and PET active hyper-glycolytic regions, with MALDI protein peaks and histology tumor features. The assumptions of tumor cells were: 1. Loss of membrane sodium pump/symporter is associated with glucose pump and loss of oxygen (low oxidative phosphorylation makes high glycolysis); 2. In tumorigenesis, low oxidative phosphorylation high glycolysis apoptosis necrosis cell proliferation cell death occurs in a sequence; 3. The events of tumorigenesis or drug antitumor action are detectable by in vivo oxidative phosphorylation and intracellular sodium (by MRI), in vivo high glycolysis and oxygen (by PET), apoptosis proteins (by MALDI protein peaks), ex vivo cytomorphometric changes of apoptosis, proliferation, necrosis, cysts (by histology); 3. Multimodal hybrid molecular imaging provides a finger print of tumorigenic kinetics and antitumor pharmacokinetics or therapeutic monitoring (Quantitative Theradiagnostics).
Relationship between sodium MRI and PET signal:
The sodium pump Na + /K + ATPase exchanges intracellular sodium across cell membrane simultaneously with glucose transport. MRI/PET signal intensities represent the less known status of sodium and glucose transport [17] . The sodium MRI T1 signal is sensitive to intracellular sodium release while PET is sensitive to glucose uptake. The echo delay time (TE) applied during multiple flip-angle gradientecho multi-slice imaging is a function of T1 or T2 signal intensity and concentration of sodium while biotransformation of 18 FDG standard uptake value (SUV) in PET is function of glycolysis.
Relationship between breast tumor protein (proteomics by MALDI) and MRI-PET imaging: Protons act as coin with two faces (one sensitive to MALDI and other sensitive to MRI-PET). MALDI imaging is protein specific to metabolic disorder of rat tumor cells in various breast malignant tumor stages with following presumptions as recently described [18] : [2, 19] .
MALDI imaging principle:
Protein detection probability from MALDI images displays several distinct protein m/z peak intensities after baseline denoising, peak intensity thresholding correction via apodization and regression or calculated normalized peak intensity with accuracy [20] .
Reference acids (hydrocinnamic acid and sinapinic acid) or (MH + +Analyte M + Analyte-H + ) show high gas phase or proton affinity (basicity) and they are desorbed and accelerated to a fix kinetic energy in a time-of-flight analyzer (a vaccum field free tube). In tube, protein ions are separated as a function of their m/z depending on velocity and time of flight as following:
where m is the ion mass, z is number of charges, V is source potential, t is time of flight and L is length of TOF analyzer. For unit mass, (m=1)/z is proportional with intracellular sodium (IC) MR signal intensity and PET intensity (SUV or oxygen content from glycolysis). Single proton m/z, MRI, and PET intensities are known in standard calibration [20] .
Due to possibility of multi-ionic charged proteins, laser pulse receives all charged protein ions with no delay and sends them to detector same time to detect all proteins in one step to generate high resolution m/z spectra or 2-dimensional ion density m/z maps of protein molecules from tumor tissue sample. Due to no exact internal standard, each peptide concentration is measured indirectly from peak amplitudes at different positions as representative of peptide size.
The 'relative peptide concentration' is calculated from MALDI peak as:
Suppose 's' is peptide sequence and I is intensity of MS peak.
MASCOT software for peptide mass finger printing was used to search protein analysis in terms of: 1. protein mass in range in Daltons (Da); 2. isoelectric pI of specific proteins [2] ; 3. protein hit score and matched other common peak pattern of spectra.; 4. Narrowing down number of common sharp spectral peaks per protein and find matched spectral peak pattern common among proteins; 5. preprocessing for deconvolution, baseline correction and noise peak removal; 6. identification of m/z peak intensities; 7. narrow down search of protein specific m/z peaks [2] .
MALDI in protein ion 3D display: After imaging, coregistered tumor sections at same histology match are placed on MALDI plate and laser beam rasterizes over tumor sections in MS spectrometer at different locations to generate an array of MS peak digitized points appearing as distribution maps of proteins as outlined in Fig. (1) .
MATERIALS AND METHODS
Tumor propagation and Microimaging: Techniques were reviewed from patents (see Table 1 ) for MCF-7 induced tumor propagation inlocally raised rats and treated with Taxotere ® (Aventis Pharmaceuticals, Bridgewater, NJ) similar to earlier report [20] . The sodium MRI (1 mm slice) and 18 FDG-PET images of MCF-7 induced rats (n = 6) and control rats (n = 3) were scanned with Animal Care and Use Committee guidelines in force at Columbia University as described in previous report [1, 21] . In brief, rats were placed inside 26 mm birdcage coil and imaged in 4.23 T clinical imager to generate T 1 , T 2 parametric images. Sodium IR MRI T 1 maps were obtained using multiple flip-angle gradientecho multi-slice images (128 128 10, FOV = 25 25 1.8 mm). For T1 map, TR = 200 msec, TE = 4.5 msec, = {15°, 30°, 45°, 60°, 75°, 90°}) were chosen. For T2 map, TR = 4 sec, TE = {12, 24, 36, 48} msec) were chosen.
The T1 maps were generated by non-linear fitting the gradient-echo multi-slice images (T1 weighted images) to the following function:
where, T 1w ( ) is the per-voxel measured signal at each flip angle, TR is the repetition time for the MR experiment, T 1 is the fitted parameter, and C 0 and C 1 are constants used to account for baseline signal and measurement offset, respectively. T1 values were measured at each voxel on voxel-by-voxel T1 map.
The T 2 maps were obtained by non-linear fitting the gradientecho multi-slice images T1 weighted images to the following function:
where, T 2w (TE) is the per-voxel measured signal at each echo-time, TE is the echo-time for the MR experiment, T 2 is the fitted parameter and C 0 and C 1 are used to account for baseline signal and measurement offset, respectively.
After magnetic resonance imaging, each animal was immediately killed, perfused with saline and frozen in an ice block to minimize any postmortem protein degradation. The frozen tumor tissue was sectioned to 20 micrometers thick on a cryo-microtome (Leica) in the cranial-caudal direction.
Tumor sections from each segment in the blockface volume were prepared for MALDI-IMS acquisition. MALDI IMS images were taken and collected every 150 micrometers in an anterior to posterior fashion. The tumor tissue ion images were collected at lateral resolution of 150-300 micrometers, with each pixel represented by accumulation of 300 laser shots. MALDI spectrum of mass-charge ratio data was processed for spectral smoothing and base-line correction in MATLAB and ProTSData (Biodesix) software (see Fig. 1 ). MicroPET facility in Milstein Hospital building was used to demonstrate hyper-or hypometabolic tumor regions in Taxotere ® treated Sprague-Dowley rats after injection of 100 Curie 18 FDG by intravenous route.
Technique Development for MALDI-IMS Data Acquisition
Mass spectrometer was tuned and controlled in its operations for TOF-MALDI MS spectroscopy mode and it was also used as the data source to acquire, process, store, and print. Most of the analog electrical signals reach the computer after analog-to-digital converter is used. In reverse order, digital signal can be converted to analog signal. However, in MALDI, transputer is used as digital device to convert its electrical signals in the form of pulses or proportional m/z peak intensities. A mass spectrum has m/z values (peaks) each showing peak height proportional to number of protein ions with unit charge. The m/z peak shapes from selected tumor tissue locations on MALDI slide (protein molecules) generate a set of electrical signals at preset voltage (checking is important in different Scanning modes). By manipulation of mass spectra data, accurate mass measurement was done (relevant peak sorting by thresholding at a certain peak height) to gather important m/z peaks and compare with calibrated reference peaks of reference CHACA and HABA calibrated compounds. By 'match and try' a set of peptides was selected to determine the protein make-up (proteomics finger print) using MOSCOT and Swiss library search for molecule identification as shown in Fig. (1) at the bottom.
Tumor tissue samples were prepared for MALDI data using techniques described in a previous study [1] . Collected tissue sections were transferred using rice paper to gold-coated MALDI target plates (Applied Biosystems Inc.) and spray-coated with a 25 mg/mL sinapinic acid matrix solution prepared in 60% acetonitrile, 0.5% trifluoroacetic acid. Approximately 10 mL of matrix solution were needed to produce a homogeneous matrix crystal layer. Matrix coated samples were then analyzed on a linear MALDI-time-of-flight mass spectrometer (Autoflex II, Bruker Daltonics Inc.) equipped with a Smartbeam™ laser operating at 100 Hz. Each peak was analog signal varied from base line. First signal was digitized and simulated by Monte-Carlos approximated 3D reconstruction volume. An analog to digital converter (ADC) converted a continuous signal to series of digital pulses in which the voltage represented snapshots of the biochemical nature of molecules as analog signal taken at regular time intervals (discrete digital readings in Fig. 1 ). The voltage from ion detector varies as ions were introduced and focused. As each m/z value was focused, a peak ion current generated the voltage change proportional to each m/z amplitude or peak intensity on spectra.
3D Spatially Resolved MALDI-IMS Post-Processing
Image post-processing was performed to recreate spatially resolved 3D MALDI IMS data. The first step was to align the MALDI mass spectra to the targeting image used by the mass spectrometer. The MS spectrometer reports the origin of MS spectra within the tumor field-of-view (FOV) in terms of internal motor coordinates. These tumor locations are used as training fiducials related to a targeting image(s) selected at the time of data acquisition. Pixel locations of the training fiducials in the targeting image were registered to their corresponding motor coordinates using an affine alignment. Tumor locations in internal motor coordinates within the mass spectrometer were transformed into image's pixel space (spatial locations) by alignment via contour based registration of shape features in each image of the targeting images as reconstructed block face image (outline of the rat tumor section). The contours were manually highlighted by iterative closest point (ICP) algorithm to align the corresponding contours in targeting images. This transformation placed the targeting image coordinates into block face image coordinates. The slice location in zdirection or axial direction was annotated for each slice number and the thickness of each slice to append it with each 2D block face coordinate to provide a 3D physical space location for each MALDI IMS spectra or a continuous transformation from the 2D motor coordinates to 3D animal specific coordinates.
Breast Tumor 3D Reconstruction Volume
Spatially resolved three dimensional volume reconstruction MALDI IMS images were reconstructed by post-processing steps. The ice-block was manually set across a stationary blade to section the rat tumor tissue at the interval of 1 mm distance and 5 micron thickness. Retrospective inter-slice registration was used to align consecutive blockface images. For each set of blockface images, the second slice was aligned to the first slice. The registered MRI image slice was used as the target blockface to align the next consecutive histology slice in the tumor volume. This process was iterated upon until all of the MRI images had been registered, and concatenating these together yielded an accurately reconstructed blockface volume.
Tumor Registration
Three dimensional MALDI-IMS and magnetic resonance images were correlated by geometrical deformation and rigid co-registration (tumor high signal intensities on images as solid object) of blockface volume (PET frames) to the magnetic resonance volume (3D slices) of tumor. The heterogeneous tissue nature of breast tumor prevents centroid registration large scale deformable changes in anatomy and deconvolution method cannot realign them. A six-degree of freedom rigid body (position and orientation) normalized mutual based registration was used to associate and align implicitly the blockface PET data (moving frames in 'x' angular direction) with magnetic resonance volumes (ascending image slices in 'z' direction) shown in Fig. (3) .
Registration algorithms: IDL (Research Systems, Inc., Boulder, CO) on Pentium IV platform was used to use Automated Image Registration (AIR) algorithm and mutual information (MI) algorithm for following subsampling at coordinates 884, 442, 221, or 111 (XYZ subsampling) after prealignment by manual reorientation of tumor volumes selected in the 'capture range' as reported elsewhere [22] . Rigid geometric transformation was used using six SUV and MRI imaging characteristics without smoothing by AIR and MI algorithms for 'convergence optimization' method [23] . However, singular value decomposition (SVD) algorithm was used to estimate the registration errors to give "perfect" registration transformation matrix [24, 25] . This transformation was applied to a set of points spaced in and around the mouse tumor. The SVD-transformed set of points was then retransformed with the inverse of the transformation matrix arising from the multimodality registration to visualize tumor pixels. The mean Euclidean distance between these final points and the maximum distance between these points measured the registration accuracy and the "functional performance" of both algorithms [26] .
Histology features and tumor evaluation criteria:
A stereotactic MRI-PET match criteria was applied at different 16 locations of each tumor on histology slide to indicate different tumor features [27] .
Registration and similarity match: Tumor was assumed as rigid body. Based on rigid body registration principle, first tumor anatomic features were segmented from a MRI data set. Intensity-based, pattern-matching algorithm was used for inter-slice registration based upon Normalized Mutual Information [28] . NMI was optimized for x-y translation and in-plane rotation to register sequential images in the reconstruction process. The specific implementation of the algorithm used in this paper was provided by the Insight Toolkit (http: //www.itk.org). It is important to note that registration via NMI requires no fiduciary systems [29] .
Validation method: For validation of PET, MRI image intensities, biotransformation was optimized and registration methods were compared to the ground truth histology sections and registration accuracy was evaluated by root mean square (RMSE) as described earlier [21] .
Imaging and histology data of tumor area with different cytomorphic features were compared by image processing using Optimas 6.5 and statistical correlation was calculated using PRISM 3.03 softwares.
RESULTS
Reviewed data showed that subcutaneous tumors measured 0.1 to 0.5 cm in diameter as shown in Fig. (2) . The MRI and PET image acquisition systems generate images in different format so making intrinsic MRI, PET image registration difficult with blockface of tumor on microtome for histology. The blockface volume reconstruction was completely automatic. Normal rat images did not show hyperintense regions. The tumor regions on MRI and PET images were prealigned by manual reorientation using tumor shape as pseudo marker as shown in Figs. (2, 3) . The breast tumor areas in five rats were selected to image the whole tumor mass in each. The volume 'trimming' removed the extra image points not common to both PET and MRI data sets from tumor. The rigid geometric transformation by AIR and MI algorithms generated 'convergence optimization'of common data points of tumor visible on both MRI and PET images as shown in Figs. (1, 2) . The singular value decomposition (SVD) algorithm estimated the registration errors up to 10.5% and generated registration transformation matrix by applying transformation to a set of points spaced in and around the breast tumor. The transformation matrix visualized the tumor pixels up to 1.5 mm. The mean Euclidean distance between these final points in fused coregistered images and the maximum distance between these points measured up to +10% accuracy as "functional performance" of SVD algorithm.
Taxotere effect on 18 FDG PET hyperintensities (SUV values): Hyperintensities on MCF-7 induced rat tumor in vivo dynamic PET images are shown in Fig. (2) . The locations of tumor were distinct and measurable with resolution of 0.5 mm, as shown in Fig. (2) . After segmentation, control breast tumor showed distinct tumor boundaries. Different colors indicated the metabolic activity distribution at different tumor locations. In 24 hours post Texotere treated rats the tumor size was reduced in comparison with untreated tumor bearing control rats at same location as shown in Fig. (3) as extracted tumor areas. The distribution of metabolic activity at different tumor location a -d was significant to correlate these malignant regions and MRI signal intensities as shown in Table 1 . The distribution of both sodium MRI signal intensities and PET hyperintensities SUV values in different tumor locations was significant to correlate MRI-PET visible regions with premalignancy characteristics by histology shown in Table 2 .
Taxotere effect on extracellular and intracellular sodium image intensities: High MRI signal intensities are shown on MCF-7 induced rat tumor in vivo extracellular (EC) sodium and intracellular (IR) sodium images in Fig.  (3) . The sodium MRI signal intensities of tumors were comparable with sodium phantom images at optimized inversion time (TI = 25 ms) and echo time (TE = 10 ms). The IR-MRI images showed better contrast between breast tumor and normal rat tissue compared to the EC-MRI images on T1 weighted contrast scan settings as shown in Fig. (2) .
The sodium MRI images of in vivo MCF-7 tumors are shown in Figs. (2, 3) , at baseline, 24 hours and 48 hours after intravenous injection of 1 mg/ml in 0.25 ml of Taxotere in the femoral vein. Both EC-MRI and IR-MRI image showed contrast resolution similarity. However, contrast enhancement is shown as the IR-MRI line profiles following Taxotere chemotherapy in Fig. (3) . The visible intracellular sodium[Na] i increase was distinct by IR-MRI imaging but less visible by EC-MRI imaging after Taxotere chemotherapy. Using a standard high temperature sensitive superconducting copper coil enhanced the signal-to-noise ratio of IR-MRI images by a factor of 10.5 times in less imaging time by a factor of 10 times.
Tumor histology evaluation criteria and MRI-PET imaging comparison:
The histology distinguished the tumor necrosis, apoptosis and different malignant tumor features under high power field microscopy as shown in Fig. (2) in pre-treatment tumors. Different tumor features were measured of cyst size up to 40-200 microns, membrane blabbing, beaded nuclei 2-5 per cell and extracellular space up to 100-300 microns observed under high power field on slide and each division showed distinct MRI/PET signal intensities as shown in Table 1 . The cyst showed low MRI signal intensities and extracellular space showed high MRI intensities. The PET showed high signal intensities in both cyst and extracellular space features. However, necrosis, cell proliferation regions showed isointense MRI images as shown in Fig. (2) coregistred with panels (i-m for different stages) on histology. The tumor evaluation 'quantitative molecular imaging criterion' suggested a simple, reproducible tumor grading scheme with minimum intraoperator bias to evaluate the tumor features and changes after anticancer taxotere drug effect on tumor chemosensitivity. The delineated areas on both histology digital images and MRI-PET fused images showed a comparable tumor morphometric measurement with r 2 = 0.997, P value = 0.002 as shown in Figs. (2, 3) . However, histology method showed 20% less areas due to shrinkage of tumor tissues as shown in Figs. (2, 3) .
Registration error and accuracy measurement: Rigid registration method showed two different points annotated as bright tumor regions and dark tumor regions as PET images. The brighter point set included all brighter nodes of the tumor from M original . The dark point set included all dark-gray voxels of tumor from tumor from M original . The RMSE accuracy was measured in millimeters for rigid registration method [1] . The tumor regions from M original were registered with static (P tr and P em ) PET transmission and emission volumes.
Monitoring of therapeutic response by tumor histology and signal intensity changes in IC Na MRIand PET images:
The effect of Taxotere after 12 hours was not visible by MRI and PET techniques. Taxotere enhanced the localized tumor signal intensities on intracellular sodium on MRI by 25% and glucose uptake on PET by 10% after 24 hours. However, later the effect was reduced after 48 hours as shown in Fig. (3) . The post treated 48 hours end-point histology suggested the tumor cytomorphology features of enhanced apoptosis, cyst size and mitotic index comparable with enhanced IR sodium and PET signal intensities at these tumor locations. Apoptosis was evident by Annexin V immunostaining and cell cycle CAS 200 histograms showed M and S phases of neoplasia in selected histology matched tumor regions shown in Fig. (2) . However, these less defined tumor tissue features were not feasible for histology and imaging co-registration.
MALDI imaging with MRI-PET and histology:
The excised tumor specimens and their matched locations in MRI-PET showed a coregistered data set of 'MALDI peak profile and histology cytomorphic features' on small tissue sections are shown with i-m panels and MALDI peak spectra in Fig. ( 2) in high power microscopy fields. Same data is shown for registered MRI-PET signal intensities with MALDI array and registered histology details of each cytomorphic feature shown in Fig. (3) and Table 2 . For achieving tumorigenic protein details from MALDI images, individual peaks A and B were characterized to sort out from electrophoresis out of several spots of proteins as shown in Fig. (2) .
Between the individual m/z values (between the peaks), no voltage change was observed because no ions arrive at the detector. The time between individual peaks was very much longer than the time taken by one peak width. The base line correction eliminated the noisy part of base line to record desired signal. Such processing was useful in identification of specific pattern of ion peak output voltage values for specific molecule in the sample. A total of 3 peaks (m/z with 6,630, 8,139 and 8,942 Da) were screened out by 'support vector machine' to construct the classification model with high discriminatory power in the training set as shown in Figs. (1, 2) . The sensitivity and specificity of the model were 96.45 and 94.87%, respectively, in the blind-testing set. The candidate biomarker with m/z of 6,630 Da was found to be down-regulated in breast cancer tumors, and was identified as apolipoprotein C-I (unpublished data). Another two candidate biomarkers (8, Figs. (3, 4) .
MALDI Image Processing:
Post-processed peaks and digitized ion images (m/z peak specific) for tumor volume reconstructions represented a set of peptide(s) and protein(s) indicated by respective spectral m/zpeaks as shown in Fig.  (2) . Monte-Carlos digitization performed well to generate point spread or point on MALDI-IMS image. Several cycles ofiterations (N = 10) further enhanced the sensitivity of protein or peptide specific peak selection and digitized peak point as simulated MALDI image as shown in Fig. (3) .
MALDI IMS imaging:
Integrating three-dimensional volume reconstructs of spatially resolved MALDI IMS ion images of whole breast tumor with fused high resolution MRI-PET images showed correlation between proteomic profiles with in vivo distribution of sodium and glucose uptake shown in Figs. (1-3) . Each laser spot on MALDI plate corresponds to a pixel in a two-dimensional array of protein molecule or peptide make-up profile (proteomics content) of the selected point (on tumor slice on MALDI plate) predicting m/z peaks at every pixel. Three dimensional tissue volume reconstruct (display of simulated m/z data in 3 dimensions) by MALDI IMS construct provided the information of the MALDI IMS data or simulated 3D spatial finger print of proteomics relationship (protein pattern) with reconstructed 3D tumorigenic events in tumor 3D tissue volume. The MALDI-IMS information enhanced the protein-specific mass spectra as 3D anatomical distribution of protein annotation or distribution map for proteins (m/z) as visual ion volumes. Spatially resolved MALDI IMS data and volume rendered ion volumes fused with in vivo MRI-PET data suggested the possibility of breast tumor proteins as associated with structural and functional events in the tumor cells (sodium symporter-glucose uptake status by MRI-PET) during tumorigenesis as drug evaluation testing method (see Figs. 2, 3) .
The tumor areas with presence of tumor-specific proteins (apoptosis related high protein concentration or high 'm/z' ion volume on MALDI image) showed correlation with T1 contrast IC sodium variations in magnetic resonance and blockface volumes in the overlay renderings. In 24 hours post-texotere treated animals, IC sodium variation was maximum without change in MALDI image proteomics profile. In selected voxels inside breast tumor and treated breast tumors showed protein peak (m/z) ion intensity values + 3 sd above mean value. Unpaired 'f-test'and 't-test' showed unequal variances of tumors (n = 16) vs normal tissue (n =3). Magnetic resonance images of rat breast tumor on a 4.23 Tesla clinical imager produced structural quantitative sodium parametric MRI images while PET generated physiological distribution of glucose uptake. Parametric comparison on MRI-PET images showed pixel intensities in both RGB colors and gray scale as biomarkers. 
C
Statistical analysis of MALDI data showed spectra (in the range of 1-20 kDa) baseline subtracted and averaged peaks by centroid function gave peak resolution (FWHM) 1000-1500 (S/R = 8 for m/z 950 peak signals) on linear TOF mode setup as shown in Figs. (3, 4) . Three MALDI peaks showed frequency graph of Gaussian distribution showed averaged distribution 0.83(95% confidence intervals 0.78-0.88) and peak intensities differed CV 20% with score between 0.7-1.0 by linear regression. It means lowest and highest relative intensities differ each other for < 30%. Cartesian plot analysis for influence of m/z over similarity score of each peak (within 0.7-1.0 range) showed reproducible data in tumors from rats as shown in Fig. (5) .
DISCUSSION
The integrated MRI-PET-MALDI data fusion for evaluation of rat breast tumor is explored to identify apoptotic protein(s). Explanted MCF-7 cell lines are routine in experimental rat breast tumor propagation and testing anticancer drug chemosensitivity [27] . In vivo Taxotere treatment experimental doses used in rats were comparable to human clinical doses in previous study. Early tumor features and malignant lesions in rats induced with MCF-7 cell line showed biological, morphological similarities with many characteristics that closely mimic human breast cancer [1] . The proteomics information of MCF-7 cells is well documented by MALDI MS spectroscopy and PEG electrophoresis to identify potential protein biomarkers to predict response to chemotherapy in breast cancer [30] [31] [32] . Present study also indicated the possibility of protein identification in tumor by MS peaks and presence of different proteins by PEG electrophoresis.
The selection of breast tumor areas with high signal intensity pseudo markers on MRI and PET images provided fine tumor alignment. However, better spatial resolution was still a challenge. The 'convergence optimization' of both MRI and PET common data points was reasonable to fuse them and approach was comparable with previous reports [21, 23] . The SVD functional performance was comparable to calculate registration error with acceptable accuracy [33, 34] .
The distinct sodium MRI and glucose uptake PET signatures in tumor solid sites and semi-solid or fluid filled cyst regions in breast tumors were comparable with previous reports of different pre-malignant or malignant stages in tumor [1, 14, 20] . The tumor chemosensitivity to Taxotere was associated with solid tumor shrinkage or tumor cyst development showing up with low IR-MRI signal and enhanced EC-MRI signal on T1 weighted images. This observation corroborated with other reports indicating more loss of bound sodium in breast tumor after 48 hours than at 24 hours [1, 20] .
The MRI/PET 'similarity measure' and validation by root mean square error (RMSE) was feasible for PET and MRI tumor size [35] . However, the PET method used an assumption that deformation to the intermediate tumor graydark point was proportional to the full deformation to the dark tumor regions in images. Poor MRI/PET similarity measurement accuracy artifacts were minimized by simulating MRI tumor size from segmented tumor size or The major three peaks were visible at 11250(A), 13750(B), and small peaks (C) at 13700 and 15200 positions (in m/z) on spectra as characteristics of rat breast tumor proteins shown in Figs. (3, 4) .
computing NMI between static PET transmission volume (P tr ) and small MRI volumes chosen along the line of maximum 0.6 -0.9 voxels away from zero translation in order to avoid segmentation errors as reported elsewhere [28] . The rigid registration of whole tumor borders in all directions also improves measurement accuracy [29] . Moreover, the deformations were restricted to anatomically tumor areas by locating the sphere centers on the triangle nodes.
The quantitative criterion served as numerical approach to measure tumor areas or size showing different tumor cytomorphic features, MALDI peaks and MRI/PET signal intensities at matched locations up to 100 micron resolution in pre-treatment or post-Taxotere treatment. Main features were: cyst hypointensity on MRI; necrosis with cell proliferation hyperintensity on PET, semisolid mass hypointensity on MRI and PET both modalities; Time of Flight-MALDI (TOF-MALDI) or Electrospray Ionization (ESI) Mass Spectrometry of phosphopeptides from trypsin protein digests to have a large number of peaks; distinct cytomorphic features of apoptosis, necrosis, proliferation, cyst mass, aneucleosis by excised tumor histology. Earlier studies showed MRI-PET with histology as powerful tools for characterization and identification of phosphorylation sites [35] . Status of MALDI imaging as adjunct still remains disputed because of several artifacts including low intrinsic abundance, inefficient ionization, and/or signal suppression of most common peptides may limit or even prevent detection, unless the apoptosis sensitive phosphopeptide(s) content is significantly enriched by electrophoresis prior to MALDI analysis. confirmation and classification model with high discriminatory power in the training breast tumor data set [35] . Investigators reported primary invasive cancer proteins (C6, C11, C14, C16, and C26) different from five normal ones (N4, N15, N32, N33, and N36). Mass spectra on IMAC-Cu chip arrays using 1 μg of total protein showed protein expression profiles confirmed the breast cancer by two clusters: C6, C14, N32, N33, and N36 and the other C11, C16, C26, N4, and N15. A supervised cluster analysis by ProPeak (3Z Informatics, Charleston, SC) and biomarkers both separated the cancer data from noncancer data [35] . The sensitivity and specificity of the model were reported 96.45% and 94.87%, respectively, in the blind-testing set.
The candidate biomarker with m/z of 6,630 Da was found as down-regulated in breast cancer patients, and was identified as apolipoprotein C-I. Other two candidate biomarkers (8, 139, 8, 942 Da) were found up-regulated in breast cancer and identified as C-terminal-truncated forms of C3a and complement component C3a, respectively. In addition, the level of apolipoprotein C-I progressively was decreased with the clinical stages I, II, III and IV, and the expression of Cterminal-truncated form of C3a and complement component C3a gradually increased in higher clinical stages [18, 35] .
3D MALDI protein sorting and display by Monte Carlos distribution as digital image of specific protein peak (appeared as digital map similar with MRI-PET digital images) was similar to previous study on 3D volume reconstruction of proteins and peptides of breast cancer [19, 36] . Sinha et al. developed an iteration method to display phosphopeptide Pea15 and Fabp5 proteins of glioma and confirmed them by microscale affinity capture technique and calibrated with standard phosphopeptides (phosphoserine, phosphothreonine, and phosphotyrosine) [2] . Using same approach in MCF-7 induced breast cancer model of explants tumor we performed proteomics analysis to identify and characterize tumor-associated protein variants associated with apoptosis by two-dimensional electrophoresis (shown in Fig. 1) and MALDI mass spectrometry. We characterized the influence of N-methyl-N-nitrosourea (genotoxic nitroso compound) as tumor-inducing agent on the protein pattern of breast malignant tumor in rat. We found several tumor apoptosis-associated variants AKR1C1 or -C3, AKR1B1 representing the proteins of the aldo-keto reductase superfamily. We believed that apoptosis-associated protein induction and/or protein inhibition were related to the carcinogen MCF-7 bio-oxidation used for tumor induction. The most prominent tumor-associated protein, rat aldose reductase-like protein-1 (rARLP-1) (69% sequence identity to lens aldose reductase) and three additional types of rARLP-1 were detected in nitroso compound-induced rat tumors, while rat aldo-keto reductase protein-c (Rak-c), a novel tumor-associated variant (65% sequence identity with 3 -hydroxysteroid dehydrogenase) was identified in Nmethyl-N-nitrosourea-induced breast tumors (unpublished data). Reduced 3 -hydroxysteroid dehydrogenase and 4 -3-ketosteroid-5 -reductase enzymes both were tumor-specific detoxification independent of MCF-7 induction. We believe that MCF-7 carcinogen leaves a specific fingerprint(s) at the proteomics level to manifest breast tumors. In contrast, members of the aldo-keto reductase superfamily were not reported as associated with MCF-7 induced changes in proteomics peaks in breast tumor [37] . At this point much remains to explore and investigate the apoptosis proteins in breast tumor associated with induction or due to MCF-7 induction.
3D volume construction and 3D MALDI imaging coregistration with MRI/PET digital images was somewhat trivial because of MALDI sensitivity to protein mass; MRI sensitivity to protein bound sodium and PET sensitivity to radiolabel [18F] bound glucose. Moreover, apoptosis associated proteins and intracellular sodium bound proteins may or may not be dependent on glucose uptake (sodium symporter) or sodium pump and oxygen state in cell [38, 39] . Earlier reports suggested the active role of intracellular sodium and elevated glycolysis and reduced apoptosis in tumorigenesis and reversing or arresting or slowing down by anticancer drug chemosensitivity [40] .
However, coregistration of 3D co-ordinates on MRI/PET and histology digital images was decisive and comparable with other report [41, 42] . The present study extended one more imaging MALDI modality to get composite information of tumor protein molecular details. The relationship of PET (18-FDG-glucose signal intensities) and MRI (sodium signal intensities)with MALDI (protein distribution at different tumor locations) and matched cytomorphological details (histology) may serve the purpose of cytomorphometrics and glycolytic tumor characterization with location of proteins (proteomics maps) to monitor realtime tumor chemosensitivity as a tool with possibility of in vivo diagnostic and therapeutics interpretation.
The real time monitoring of docetaxal (Taxotere) drug chemosenstivity effect during 0-48 hours was demonstrated in present study in terms of shrunken tumor mass by sodium MRI and decrease in hyperglycolytic tumor tissue with possible MALDI-IMS visible premalignancy malignancy specific tumor protein(s). However, the chemosensitivity effect was reduced at 48 hours end-point in comparison with chemosensitivity effect at 24 hours end-point. The tumor ex vivo cytomorphometry features added quantitative evaluation of drug chemosensitivity and supported to our previous observations [1, 20, 43] .
However, there are several limitations of the use MRI/PET and predicting the tumor features. First, the tumor shrinkage during tissue processing of 4 micron tissue histology section limits the measurement of tumor histology area compared with 1000 micron MRI images. Second, 18-FDG PET images are dynamic and their projection images limit the correlation of glycolysis rich signals with sodium MRI signals. Third, different tumor features observed under high power fields may not always true representative of tumor staging as assumed in criteria. Fourth, identification of major carcinogenic responsible tumor proteins is a challenge because MALDI peaks are showing m/z peaks of proteins or peptides from a very small tumor region (difficult to take away specimen from big mass of tumor) while PEG electrophoresis protein/peptide map shows presence of tumor proteins (with different pI) in large number without any confirmation of responsible tumorgenic or apoptotic or premalignant protein(s). However, the intracellular sodium and glycolysis relationship stands valid in progressing tumor cells as indicated earlier [43] . However, it remains to determine if tumor proteomics signatures have any impact on in vivo MRI-PET imaging signal contrast. Other important issue was how spatial and quantitative information from proteomics may extend the protein predictability and implications of in vivo MRI-PET image contrast distribution due to presence of odd numbered sodium nuclei and radiolabeled glucose. Proteomics automated image processing data [44] from in vivo MALDI-IMS studies may have potentials to test drug action or to predict functional regulatory protein information responsible of tumor apoptosis and angiogenesis (proteomics profiling), signaling mechanism and molecular mechanism of programmed tissue degradation (protein expression) and cancer protein mapping [45] [46] [47] [48] [49] [50] . The spatial distribution of tumor cell protein molecules as false color maps can open window to the visible biochemical changes with insight of biophysical basis of MRI image contrast and physiological basis of PET contrast [51] . In future, technical advancements may accomplish the purpose of quantitative noninvasive MALDI imaging combined with multinuclear in vivo protonintracellular sodium and glycolysis imaging indicators of tumorigenesis (apoptosis, necrosis, proliferation, premalignancy or malignancy) to test anticancer drug chemosensitivity [52] . It remains to see the new inventions how advanced techniques solve the problem of integrating in vivo imaging data with ex vivo molecular imaging data to construct threedimension tumor volume of molecular details or IMAGINGTHERAPROTEOMICS to test anticancer drug effects.
CURRENT AND FUTURE DEVELOPMENTS
Recently several inventions and patents have suggested the possibility of multimodal imaging by integrating digital data from morphometric imaging with molecular imaging such as MALDI, immunostaining. The present review showed the distribution of 18-FDG-PET and sodium MRI signal intensities in tumor as measurable and diagnostic by imaging methods. Still there is no consensus on best configuration for PET/MRI system. There are three main approaches of PET/MRI integration architecture: sequential, insert and integrated types [53] . Major challenges are: 1. Potential cross talk effects in front-end electronics due to fluctuations in light yield of scientillators in PET detectors caused by rapidly changing MR gradients and RF signals; 2. Magnetic inhomogeneities; 3. Compensation of Eddy currents and better shimming; 4. Better PET attenuationscatter-random coincidence correction algorithms; 5. Detector technology with matching scintillation crystals combined with less sensitive light sensors. In future new technology of magnetic field insensitive avalanche photodiodes, design shielded PET electronics will be available to avoid electromagnetic interference. In future, quantitative MRI-PET-MALDI-histoimmunostaining criterion can or will distinguish apoptosis-rich and benign or malignant tumor features for theradiagnostics. Sodium MRI and PET image intensities is a new information showing positive correlation with histology and apoptosis premalignancy proteomics indices as rapid drug monitoring time-dependent assay. In this direction, recently inventors modified and suggested design of transparent MALDI slides [54] , antibody-peptide conjugate mediated MALDI imaging by fast fragmentation method [55] and new thresholding techniques of MALDI peak selection. 3D digital mapping of MALDI is in infancy.
CONCLUSION
The physical basis of MALDI imaging and MRI-PET data integration is explored and patents are reviewed with a focus on the progress of quantitative MRI-PET and MALDI protein detection applications to test anticancer drug. Review of patents showed the approach of integrated MRI/PET imaging and immunostaining, histology and MALDI data may show correlation as sensitive, tumor specific, accurate reproducible and precise to define apoptosis in theradiagnostics of breast tumors in experimental rats.
